Yunbai Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company" or "Yunbai Pharmaceutical") held the 10th meeting of the 10th Board of Directors on October 29, 2024, where it approved the proposal regarding the handling of Yunbai International's convertible bonds. The Company agreed to exercise its rights to convert HKD 500 million of convertible bonds held in Yunbai International Limited (formerly known as "Wanlong Holdings Group Limited") into shares, in accordance with the relevant agreements, including the supplemental agreement to the convertible bond subscription agreement. The Company will implement the subsequent conversion and related trust product matters after the public shareholding of Yunbai International meets the conversion requirements as stipulated in the agreements.
000538SZSE
Progress Announcement on Subscription of Convertible Bonds of Yunbai International Limited
✨ AI Summary
Yunbai Pharmaceutical Group Co., Ltd. announced the approval of a proposal regarding the handling of convertible bonds of Yunbai International Limited. The company will convert HKD 500 million of convertible bonds into shares, resulting in a significant increase in its shareholding from 25.11% to 40.32%. This conversion meets the public shareholding requirements of the Hong Kong Stock Exchange.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.